Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Csl Ltd (CSLLY)

Csl Ltd (CSLLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 92,771,560
  • Shares Outstanding, K 910,239
  • Annual Sales, $ 9,151 M
  • Annual Income, $ 2,103 M
  • 60-Month Beta 0.59
  • Price/Sales 10.34
  • Price/Cash Flow 37.44
  • Price/Book 11.67
Trade CSLLY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 09/04/20
  • Annual Dividend & Yield 0.94 (0.90%)
  • Most Recent Dividend 0.470 on 03/03/21
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
98.7400 +5.17%
on 03/30/21
107.3500 -3.27%
on 04/16/21
+4.5100 (+4.54%)
since 03/19/21
3-Month
94.0500 +10.41%
on 03/08/21
115.0000 -9.70%
on 02/18/21
-1.1100 (-1.06%)
since 01/21/21
52-Week
91.0400 +14.06%
on 05/29/20
117.9800 -11.99%
on 11/24/20
+7.9800 (+8.32%)
since 04/21/20

Most Recent Stories

More News
Seqirus Publishes New Real-World Evidence Supporting the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Clinical Infectious Diseases

, /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's MF59adjuvanted, trivalent influenza vaccine (aTIV)...

CSLLY : 104.1100 (+2.15%)
CSL : 177.04 (+0.76%)
Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform

and , /PRNewswire/ -- Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial...

CSLLY : 104.1100 (+2.15%)
TRUMY : 36.6200 (-2.28%)
Europe Prothrombin Complex Concentrate Market to Grow at 10.9% CAGR and to Hit USD 398.9 Million till 2027; Rising Adoption of Advanced Bleeding Disorder Management Solutions to Fuel Growth: Fortune Business Insights(TM)

The Europe prothrombin complex concentrate market size is projected to reach USD 398.9 million by 2027, exhibiting a CAGR of 10.9% during the forecast period. The substantial advantages offered by prothrombin...

CSLLY : 104.1100 (+2.15%)
Animal Health Market size 2021 | Is anticipated to reach USD 67.56 billion with a CAGR of 6.3% by 2026

The global animal health market size is anticipated to reach USD 67.56 billion by 2026 owing to the increasing number of animal health issues worldwide. Animals have always been of immense help to man...

BAYRY : 16.8100 (+2.81%)
CSLLY : 104.1100 (+2.15%)
IDXX : 541.54 (+1.74%)
MRK : 79.29 (+0.92%)
NVS : 88.66 (+0.95%)
New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season

, /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's cell-based quadrivalent seasonal influenza vaccine...

CSLLY : 104.1100 (+2.15%)
CSL : 177.04 (+0.76%)
Seqirus Ready to Reinforce Canada's Influenza Pandemic Preparedness Plans

Seqirus Ready to Reinforce Canada's Influenza Pandemic Preparedness Plans

CSLLY : 104.1100 (+2.15%)
CSL : 177.04 (+0.76%)
Global Vaccines Market Size 2021 | To Hit USD 93.08 Billion with 10.7% CAGR by 2026

The global vaccines market size is expected to be USD 93.08 billion by 2026, exhibiting a CAGR of 10.7% during the forecast period. The growing prevalence of malaria around the world is a key factor boosting...

CSLLY : 104.1100 (+2.15%)
INO : 8.88 (+2.90%)
MRK : 79.29 (+0.92%)
NVS : 88.66 (+0.95%)
PFE : 39.50 (+1.20%)
Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

, /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX QUADRIVALENT (Influenza Vaccine), the company's...

CSLLY : 104.1100 (+2.15%)
CSL : 177.04 (+0.76%)
Adult Vaccines Market Industry To Reach A New Threshold of Growth By 2030 | Merck & Co. Inc, Emergent BioSolutions Inc

A consciously conceived and designed business intelligence report titled Global  by Manufacturers, Type, and Application, Forecast to 2030 by discloses a succinct analysis of the regional spectrum,...

ABT : 121.41 (+1.18%)
ACXIF : 168.9900 (-1.00%)
AZN : 53.14 (+1.66%)
BASFY : 21.3350 (-0.30%)
CSLLY : 104.1100 (+2.15%)
GSK : 38.20 (+1.33%)
MRK : 79.29 (+0.92%)
NVS : 88.66 (+0.95%)
PFE : 39.50 (+1.20%)
SIEGY : 85.0850 (+0.94%)
VRX.TO : 30.80 (-3.33%)
Animal Health Market Size to Hit USD 67.56 Billion with 6.3% CAGR by 2026: Increasing Incidences of Zoonotic Diseases Worldwide will Drive Market, says Fortune Business Insights(TM)

The global animal health market size is anticipated to reach USD 67.56 billion by 2026 owing to the increasing number of animal health issues worldwide. Animals have always been of immense help to man...

BAYRY : 16.8100 (+2.81%)
CSLLY : 104.1100 (+2.15%)
IDXX : 541.54 (+1.74%)
MRK : 79.29 (+0.92%)
NVS : 88.66 (+0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 103.6000
2nd Resistance Point 103.1400
1st Resistance Point 102.5300
Last Price 104.1100
1st Support Level 101.4600
2nd Support Level 101.0000
3rd Support Level 100.3900

See More

52-Week High 117.9800
Fibonacci 61.8% 107.6889
Fibonacci 50% 104.5100
Last Price 104.1100
Fibonacci 38.2% 101.3311
52-Week Low 91.0400

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar